Inventor · disambiguated record
Glen Eugene Mikesell
Also filed as: MIKESELL GLEN · MIKESELL GLEN E · MIKESELL GLEN EUGENE
17 granted patents·5 pending applications·426 citations·filing 2001–2022
95Inventor score
Files withBRISTOL MYERS SQUIBB CO15TEVA PHARMACEUTICALS AUSTRALIA PTY LTD3MIKESELL GLEN EUGENE2CYTOTHERYX INC1
Top patents by PatentIndex Score
22 records- 0197US7358354B2Polynucleotides encoding BSL3BRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 15, 2008·75 cites·24 claims
- 0297US6965018B2Antibodies directed to B7-related polypeptide, BSL-2BRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 15, 2005·135 cites·28 claims
- 0396US7368554B2Polynucleotides encoding BSL2v1c2-IgBRISTOL MYERS SQUIBB CO·Filed 2006·Granted May 6, 2008·53 cites·11 claims
- 0496US7279567B2Polynucleotides-encoding B7-related polypeptide, BSL2-L165-35BBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 9, 2007·77 cites·16 claims
- 0595US7723479B2BSL3 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 25, 2010·36 cites·16 claims
- 0693US8354513B2Polynucleotides encoding BSL2vcvc-lgBRISTOL MYERS SQUIBB CO·Filed 2010·Granted Jan 15, 2013·10 cites·16 claims
- 0792US9409970B2Polynucleotides encoding BSL2v2c2BRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 9, 2016·14 cites·5 claims
- 0888US7807786B2BSL2v1c2 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Oct 5, 2010·5 cites·13 claims
- 0987US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 1087US8674076B2BSL2vcvc-lg polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Mar 18, 2014·3 cites·14 claims
- 1185US8080636B2BSL3 antibodiesMIKESELL GLEN EUGENE·Filed 2010·Granted Dec 20, 2011·7 cites·24 claims
- 1283US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1380US8664360B2BSL3 polypeptidesMIKESELL GLEN EUGENE·Filed 2011·Granted Mar 4, 2014·3 cites·4 claims
- 1474US10590183B2BSL2v2c2-Ig polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 17, 2020·0 cites·2 claims
- 1573US2020369744A1BSL2v2c2-Ig POLYPEPTIDESBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1669US9399052B2Polynucleotides encoding BSL2v2c2-IgBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 26, 2016·0 cites·25 claims
- 1769US2020079835A1B7-related nucleic acids and polypeptides useful for immunomodulationBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1866US10308702B2BSL2v2c2-Ig polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 4, 2019·0 cites·19 claims
- 1964US10400023B2B7-related nucleic acids and polypeptides useful for immunomodulationBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 3, 2019·0 cites·17 claims
- 2060US2003031675A1B7-related nucleic acids and polypeptides useful for immunomodulationFiled 2002·Application pending·0 cites
- 2154US2025027048A1Genetically Modified Hepatocyte PopulationsCYTOTHERYX INC·Filed 2022·Application pending·0 cites
- 2254US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glen Eugene Mikesell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →